Quantcast
Home / DC News / Justices: Generic drug design-defect claims preempted

Justices: Generic drug design-defect claims preempted

WASHINGTON — In a victory to generic pharmaceutical companies, the U.S. Supreme Court ruled today that state design-defect laws that impose a duty on generic drug makers to either change their labeling in violation of federal law or pull the drug from the market are preempted.


Lawyers USA has ceased publication. If you have purchased a research pass or still have additional time on your current Digital Subscription, you may access locked stories by logging in:







Scroll To Top